Drug Information

Drug General Information
Drug ID
D04WIE
Former ID
DPR000106
Drug Name
Sirna-027
Drug Type
siRNA drug
Indication Exudative age-related macular degeneration [ICD9: 362.5; ICD10:H35.3] Phase 1/2 [551694]
Neovascular age-related macular degeneration [ICD9: 362.5; ICD10:H35.3] Phase 1 [551694]
Company
Sirna Therapeutics
CAS Number
CAS 52232-67-4
SuperDrug ATC ID
H05AA02
SuperDrug CAS ID
cas=052232674
Target and Pathway
Target(s) mRNA of VEGFR1 Target Info [536057], [551694]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
Endocytosis
PI3K-Akt signaling pathway
Focal adhesion
Transcriptional misregulation in cancer
Rheumatoid arthritis
Pathway Interaction Database Glypican 1 network
HIF-2-alpha transcription factor network
S1P3 pathway
VEGF and VEGFR signaling network
VEGFR1 specific signals
Signaling events mediated by VEGFR1 and VEGFR2
Reactome Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
WikiPathways Focal Adhesion
Signaling by VEGF
Angiogenesis
References
Ref 5516942011 Pipeline of Sirna Therapeutics.
Ref 536057Future pharmacological treatment options for nonexudative and exudative age-related macular degeneration. Expert Opin Emerg Drugs. 2005 Feb;10(1):119-35.
Ref 5516942011 Pipeline of Sirna Therapeutics.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.